CURRENTLY ENROLLING HIV/AIDS NETWORK TRIALS (GREATER BOSTON - SUMMER 2019)

AIDS CLINICAL TRIALS GROUP (ACTG) CLINICAL TRIALS

1. ACTG A5345: "Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)"
ClinicalTrials.gov Identifier: NCT03001128
Selected Exclusion/inclusion criteria: 18 - 70 years old; men and women | On suppressive Antiretroviral Therapy (ART) for >2 years | CD4 ≥500 cells/mm3; nadir CD4+ count ≥200 cells/mm3 | Excluded if any plasma HIV-1 RNA at or above the limit of detection of the FDA-approved assays (limit of detection: 75, 50, 40, or 20 copies/mL) within 24 months prior to entry
Basic study procedures: Participants will pause their Antiretroviral Therapy treatment and will be monitored closely for HIV RNA rebound
Contacts: Massachusetts General Hospital, Theresa Flynn, 617-724-0072, tflynn@partners.org; or Brigham and Women's Hospital, Cheryl Keenan, 617-732-5635 ckennan@bwh.harvard.edu

2. ACTG A5359: "A Phase III Study to Evaluate Long-Acting Antiretroviral Therapy in Non-Adherent HIV-Infected Individuals"
ClinicalTrials.gov Identifier: NCT03635788
Selected Exclusion/inclusion criteria: 18 years and older | HIV-1+ | On suppressive Antiretroviral Therapy (ART) for >2 years | HIV-1 Plasma viral load (VL) greater than 200 copies/mL within 45 days prior to study entry | Evidence of non-adherence to Antiretroviral Therapy (ART)
Basic study procedures: Participants will be followed for a total of 180 weeks. They will receive Standard Of Care Antiretroviral Therapy or Long Acting Antiretroviral Therapy
Contacts: Massachusetts General Hospital, Theresa Flynn, 617-724-0072 tflynn@partners.org; or Brigham and Women's Hospital, Cheryl Keenan, 617-732-5635 ckennan@bwh.harvard.edu
AIDS CLINICAL TRIALS GROUP (ACTG) CLINICAL TRIALS

ACTG A5369: "HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons With Viral Suppression on Antiretroviral Therapy"
ClinicalTrials.gov Identifier: NCT03560258
Link to ClinicalTrials.gov
Selected Exclusion/inclusion criteria: 18 - 65 years old | HIV-1+ | On Antiretroviral Therapy (ART) for >2 years
Basic study procedures: Participants will receive a vaccine at weeks 0, 4, 12, and 24 study visits may include physical examinations and blood and urine collection
Contacts: Massachusetts General Hospital, Theresa Flynn, 617-724-0072 tflynn@partners.org; or Brigham and Women's Hospital, Cheryl Keenan, 617-732-5635 ckeenan@bwh.harvard.edu

ACTG 5377: "Pharmacokinetics of SAR441236" or "A Trispecific Antibody Against HIV"
ClinicalTrials.gov Identifier: NCT03705169
Link to ClinicalTrials.gov
Selected Exclusion/inclusion criteria: 18 - 70 years old | HIV-1+ Basic study procedures: Participants will receive an intravenous dose of SAR441236 or placebo; they will also begin or continue Antiretroviral Therapy combination therapy according to the cohort they are in
Contacts: Massachusetts General Hospital, Theresa Flynn, 617-724-0072 tflynn@partners.org; or Brigham and Women's Hospital, Cheryl Keenan, 617-732-5635 ckeenan@bwh.harvard.edu

FENWAY
"A phase IV open-label evaluation of safety, tolerability, and acceptability of a fixed-dose formulation of bictegravir, emtricitabine/tenofovir alafenamide (B/F/TAF) for non-occupational prophylaxis following potential exposure to HIV-1"
ClinicalTrials.gov Identifier: NCT03499483
Link to ClinicalTrials.gov
Selected Exclusion/inclusion criteria: 18 or older at first visit | HIV Negative | excluded if have acute or chronic Hep B or renal disease | excluded if pregnant/breastfeeding or trying to become pregnant
Basic study procedures: Subjects will receive a 28 day regimen of B/F/TAF over the course of 4 visits in a 90 day period. Visit procedures include dispensation of study drug, adherence counseling, and blood draws to test for HIV, Hepatitis, and liver function. STI testing is also available to subjects, as applicable per expression of symptoms or provider’s discretion
Contact: Johnathan Holmes, RN, 857-313-6622 jholmes@fenwayhealth.org